Matthew J Sippel bought $45k of KF
director at KOREA FUND INC. 2,000 shares at an average of $22.33, traded Oct 17, 2024, filed Oct 21, 2024.
Score components
- +15RoleDirector
- +6Trade size$45k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.4%, 3m -8.2%, 6m -6.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-115784, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | POpen-market purchase Common Stock | +500 | $22.20 | $11k | 500 | Oct 21, 2024 |
| Oct 17, 2024 | POpen-market purchase Common Stock | +500 | $22.30 | $11k | 1,000 | Oct 21, 2024 |
| Oct 18, 2024 | POpen-market purchase Common Stock | +500 | $22.40 | $11k | 1,500 | Oct 21, 2024 |
| Oct 18, 2024 | POpen-market purchase Common Stock | +400 | $22.41 | $8,964 | 1,900 | Oct 21, 2024 |
| Oct 18, 2024 | POpen-market purchase Common Stock | +100 | $22.45 | $2,245 | 2,000 | Oct 21, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.